The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C03 | Diuretics | |
3 | C03C | High-ceiling diuretics | |
4 | C03CA | Sulfonamides, plain |
Code | Title | |
---|---|---|
C03CA01 | Furosemide | |
C03CA02 | Bumetanide | |
C03CA03 | Piretanide | |
C03CA04 | Torasemide |
Active Ingredient | Description | |
---|---|---|
Azosemide |
|
|
Bumetanide |
Bumetanide is a potent loop diuretic with a rapid onset and a short duration of action. The primary site of action is the ascending limb of the loop of Henle where it exerts inhibiting effects on electrolyte reabsorption, causing its diuretic and natriuretic action. |
|
Furosemide |
Furosemide inhibits active chloride transport in the thick ascending limb. Re-absorption of sodium, chloride from the nephron is reduced and a hypotonic or isotonic urine produced. The evidence from many experimental studies suggests that furosemide acts along the entire nephron with the exception of the distal exchange site. |
|
Piretanide |
Piretanide is a loop diuretic for the management of fluid retention and treatment of mild to moderate hypertension. |
|
Torasemide |
Torasemide is a loop diuretic. Torasemide acts as a salidiuretic by inhibition of renal sodium and chloride reabsorption in the ascending limb of the loop of Henle. Torasemide leads to a gentle removal of edema and especially to an improvement of the working condition of the heart failure by reducing the preload and afterload. In patients with severe to endstage chronic renal failure there is a reduction of aterial blood pressure in addition to removal of edema and maintenance of residual diuresis. |
Title | Information Source | Document Type | |
---|---|---|---|
BUMETANIDE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
BURINEX Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
FRUSOL Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FUROSEMIDE Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FUROSEMIDE TABLETS BP Uncoated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
LASIX Solution for injection or infusion | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
TOREM 10mg Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TOREM 2.5mg Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TOREM 5mg Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
UREMIDE Tablet | Marketing Authorisation Holder | MPI, EU: SmPC |